DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of CL Wear Between Two Allergy Drops

Information source: Hom, Milton M., OD, FAAO
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Conjunctivitis

Intervention: epinastine HCL and olopatadine HCL (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: Hom, Milton M., OD, FAAO

Official(s) and/or principal investigator(s):
Milton M Hom, OD FAAO, Study Director, Affiliation: Private Practice


Comparison of two allergy drops for enhancing comfort and performance of contact lens wear

Clinical Details

Official title: Comparison of CL Wear Between Epinastine Hydrochloride and Olopatadine Hydrochloride

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind, Primary Purpose: Treatment

Primary outcome: Contact lens objective and subjective clinical performance testing

Detailed description: Contact lens patients will instill allergy drops and subjective and objective tests will be performed


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Males or females > 18 years old

- Mild to moderate dry eye symptoms

- Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

- Current use of topical cyclosporine

- Known contraindications to any study medication or ingredients

- Active ocular diseases or uncontrolled systemic disease (blepharitis patients that

are actively being treated or disease that is uncontrollable)

- Ocular surgery within the past 3 months

Locations and Contacts

Additional Information

Starting date: July 2007
Last updated: October 5, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017